Fzd4 Gene Mutation Screening for Preterm Birth Prediction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for predicting premature births are inadequate, as they do not account for genetic predispositions, leading to unnecessary treatments and complications in neonatal care, and existing screening methods fail to detect mutations associated with conditions like Retinopathy of Prematurity (ROP) and Familial Exudative Vitreoretinopathy (FEVR.
Innovation Solution
A method is developed to screen for the (P33S;P168S) Frizzled4 (Fzd4) gene variation in biological samples, which is associated with an increased risk of premature birth and ROP, allowing for targeted clinical interventions to prevent pre-term birth.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional infection-based screening methods are used to predict pre-term birth, then treatment protocols can be established, but unnecessary treatments are administered and genetic predispositions remain undetected
Solution Approach 1:
The patent changes the detection parameter from infection markers to genetic markers (Fzd4 gene variations). By screening for specific genetic mutations associated with pre-term birth and ROP, the method identifies true biological risk factors rather than treating all patients with uniform infection-based protocols, thereby eliminating unnecessary treatments while maintaining high prediction accuracy
Solution Approach 2:
The patent segments the pre-term birth risk population into genetic high-risk groups (those with Fzd4 mutations) and low-risk groups. This segmentation allows targeted clinical interventions only for those who truly need them, reducing unnecessary antibiotic treatments and associated complications in patients without genetic predisposition
2Measurement precision
If genetic screening for Fzd4 mutations is implemented, then accurate identification of high-risk individuals is achieved, but screening complexity and cost increase
Solution Approach 1:
The patent extracts and focuses on a specific, high-value genetic marker (Fzd4 gene variations) rather than performing comprehensive genomic screening. By isolating and testing for particular mutations known to be associated with pre-term birth and ROP, the method achieves high measurement precision while keeping the screening protocol simple and cost-effective
Solution Approach 2:
The patent performs preliminary identification of high-risk individuals through targeted genetic screening before clinical symptoms manifest. By detecting Fzd4 mutations early in pregnancy or pre-conception, the system enables proactive management and monitoring without requiring complex diagnostic procedures during critical periods
3Object-affected harmful factors
If targeted clinical interventions are provided based on genetic screening, then neonatal morbidity is reduced, but treatment resources must be allocated specifically
Solution Approach 1:
The patent implements a feedback mechanism where genetic screening results directly inform clinical decision-making. Patients with Fzd4 mutations receive enhanced monitoring and targeted interventions, while those without mutations receive standard care. This feedback-driven approach ensures treatment resources are allocated efficiently to high-risk individuals, reducing neonatal morbidity without wasteful resource consumption
Data Source
AI summary
A method for determining the necessity of a pre-term birth treatment is provided based on obtaining a biological sample from a subject. The biological sample is analyzed for the presence of (P33S;P168S) Frizzled4 (Fzd4) gene variation. The subject or a fetus thereof is then treated for a proclivity to pre-term birth. The Fzd4 protein itself can also be analyzed for the (P33S;P168S) Fzd4 mutation.